CBA Florida Inc. (fka CBAI)

[MrLong]

Tom, if this happens between HOTI and CBAI.OB I am rich. Remember Corcell is the only private listed in those Regenetech bioreactor patent filings.

((Maybe someone should ask CBAI if the bioreactor patent has anything to do with us. That would be a real good Q.))

What makes CBAI.OB so special that Cord Blood China Corp and CordLife Ltd sought CBAI.OB out to give away royalties and a 10% stake in the largest stem cell factory being built in China w/o CBAI.OB dropping a dime? Know-How! You and others decide but please read this and let me know if I am way ahead, on point or just dreaming. I admit I am dreaming and hoping I am correct. What makes it even more interesting is Dr. O'Neill. He was the President of Regenetech Inc., FL. Is it all just one big coincidence?

Healthcare of Today, Inc FORM S-1

STEM CELL EXPANSION FACILITIES

We are planning to develop state-of-the-art Stem Cell Expansion Facilities throughout the world. These facilities will provide doctors and research laboratories adult stem cell expansion services.

Each lab facility will be comprised of approximately 3 doctors, 6 nurses, and 8-10 lab technicians. Logistically, our plan of expansion will target major medical centers and universities. Using Regenetech's Cell Expansion technology, we are expecting to make Regenetech a world class provider of adult stem cell Expansion services.

((How many doctors at CBAI? How many techs? How many nurses?))

Is CBAI.OB one of the state-of-the-art stem cell expansion facilities? The fact remains, Corcell has the history with Regenetech and its flagship bioreactor.

THE MARKET FOR REGENETECH’S PRODUCTS


Market for Licensing of Cell Expansion Technologies

Research in adult stem cell therapy (non-embryonic) has shown: (i) that specific adult stem cells are in fact capable of tissue repair and regeneration in various organs in the human body; and (ii) injection of stem cells can reduce the side effects from chemotherapy and radiation treatment in cancer patients. There are several known therapies that use bone marrow derived adult stem cells for tissue regeneration. The most prominent of these is heart regeneration being performed at Texas Heart Institute by Drs. Willerson and Perin, and it is recognized as successful. Drs. Willerson and Perin use bone marrow as a supply of stem cells which has its problems. The cells are obtained by a process called apheresis which is drilling into the hip and extracting cells. This is expensive (about $125,000), painful, and has a mortality rate of about 5%. Regenetech’s model is to take a blood sample and expand the stem cells present in the blood in Regenetech’s bioreactor system so as to replace bone marrow stem cells for therapeutic purposes.


The market for heart regeneration procedures is approximately $60 million and is expected to exceed $100 million per year by 2013. This translates to a market for Regenetech’s expansion technology for research and treatment of $6 million increasing to $10 million by 2013. Use of Regenetech’s cells for heart regeneration would add less than 1% of cost to the total process. The market for pancreas regeneration research and treatment procedures (diabetes “cure”) is estimated to be $1 million currently and is expected to exceed $100 million per year by 2013. Use of Regenetech’s cells in pancreas regeneration will substantially reduce the cost of diabetes care and treatment. The market for all organ repair or regeneration research and therapies is expected to exceed $50 billion per year by 2013.


Within this market, the estimated cost of cell expansion research and treatment services is assumed to be $10,000,000 currently and is expected to reach $2 billion by 2013. Assuming a reasonable royalty of 5% of the total costs of cell expansion services, the total market potential for the licensing of Regenetech’s technology could be as large as $100 million per year by 2013. Regenetech believes it can capture at least 10% of this market through its research and licensing.


Regenetech plans to reach this market by licensing its technology to research institutes and organizations, pharmaceutical companies and other biotech companies that are focusing their experimentation and development efforts on different potential stem cell therapy applications. There are estimated to be 3,500 potential customers for Regenetech’s technology currently, and this figure is expected to grow to 6000 by 2013. Regenetech will seek to license its technology widely to as many customers as possible, giving some territorial or other exclusivity to front-running organizations on a selective basis, in order to participate in the customer’s success as the customer’s commercial therapeutic applications expand into the marketplace.


Market for Licensing of TVEMF Sleeve

There are currently 10 million bone repair procedures performed by veterinarians in the U.S. each year. Over 1 million of these would use the TVEMF sleeve due to the low cost in relation to the overall procedure. Regenetech expects to capture at least 10% of this market with a profit of $80-$100 per procedure.


Market for Licensing and Sale of Bio-Molecules

The market for recombinant molecules is currently over $90 billion. These molecules are used in all major surgical procedures and virtually all cell studies. Regenetech believes it can capture a minimum of 0.5% of this market. Amgen is currently the leader in the recombinant molecules market. Regenetech has approximately 7,000 grams of bio-molecules which it owns.


THE MARKET FOR DIABETES

According to the International Diabetes Federation diabetes is one of the world’s most important causes of expenditure, mortality, disability and lost economic growth.


Global health expenditures to treat and prevent diabetes and its complications total at least US $232 billion in 2007. By 2025, this number will exceed US $302 billion.

The world suffers huge losses in the form of foregone economic growth as a result of diabetes. Lost economic growth may be a relatively greater problem in poorer countries. Between 2005 and 2015, the World Health Organization (WHO) predicts net losses in national income from diabetes and cardiovascular disease of some $557 billion in China, $303 billion in the Russian Federation, $336 billion in India, $49 billion in Brazil and $2 billion in the United Republic of Tanzania (2005 ID).

These losses arise from the premature death and disability that untreated diabetes causes. Perhaps 25 million years of life are lost annually to mortality caused by diabetes. Reduced quality of life may reach a similar magnitude among the living.


If Regenetech captures only 2% of the market, it could have an income of US $4.64 billion in 2010 or very shortly thereafter and over US $6 billion by 2025. Since economic loss will be offset by Regenetech’s nominal treatment cost, Regenetech’s profit will be essentially the same as health expenditure cost.

((Tom, it says 2010. What must you have to cure diabetes? Hospitals, doctors, state-of-the-art lab, lots of storage space (250k @ CBAI.OB) to store UCBs and space to buildout for this specialty treatment lab. Is there any remote chance with CBAI.OB HQ is a HOTI Lab? Yes. If I am correct I can see and hear the CBAI.OB train on the tracks coming this way. Again, I just hope CBAI.OB is on the HOTI Regenetech tracks. Why are we in China getting a royalty? Know-how!.. hmmm?))

http://google.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHTML1?ID=6701979&SessionID=yFiYHeQJI-RlB27